Ryan D. Cassaday

6.9k total citations · 1 hit paper
138 papers, 2.0k citations indexed

About

Ryan D. Cassaday is a scholar working on Oncology, Pathology and Forensic Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Ryan D. Cassaday has authored 138 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Oncology, 57 papers in Pathology and Forensic Medicine and 50 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Ryan D. Cassaday's work include CAR-T cell therapy research (62 papers), Lymphoma Diagnosis and Treatment (57 papers) and Acute Lymphoblastic Leukemia research (50 papers). Ryan D. Cassaday is often cited by papers focused on CAR-T cell therapy research (62 papers), Lymphoma Diagnosis and Treatment (57 papers) and Acute Lymphoblastic Leukemia research (50 papers). Ryan D. Cassaday collaborates with scholars based in United States, Germany and South Africa. Ryan D. Cassaday's co-authors include Lee J. Helman, Stephen M. Hewitt, Chand Khanna, Richard Görlick, Choh Yeung, Arnulfo Mendoza, Osarenoma Olomu, Xiaolin Wan, Ajay K. Gopal and Brian G. Till and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ryan D. Cassaday

124 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis

2004 572 citations Ryan D. Cassaday et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ryan D. Cassaday United States	21	1.0k	580	456	378	354	138	2.0k
David Wu United States	21	1.1k 1.1×	556 1.0×	516 1.1×	444 1.2×	547 1.5×	65	2.4k
Carlos Bachier United States	19	649 0.6×	354 0.6×	276 0.6×	128 0.3×	459 1.3×	86	1.5k
Amanda F. Cashen United States	29	1.0k 1.0×	1.4k 2.4×	629 1.4×	193 0.5×	891 2.5×	121	2.9k
Timothy S. Fenske United States	27	1.7k 1.6×	1.2k 2.1×	435 1.0×	138 0.4×	543 1.5×	162	2.6k
Toshiki Uchida Japan	26	650 0.6×	591 1.0×	617 1.4×	241 0.6×	675 1.9×	86	1.9k
József Zsíros Netherlands	18	657 0.6×	493 0.8×	443 1.0×	198 0.5×	73 0.2×	49	1.9k
Michel Symann Belgium	21	1.3k 1.2×	508 0.9×	371 0.8×	133 0.4×	495 1.4×	95	2.2k
Anne Tierens Norway	29	778 0.8×	914 1.6×	504 1.1×	174 0.5×	590 1.7×	101	2.2k
Allen Buxton United States	21	977 1.0×	362 0.6×	1.0k 2.3×	308 0.8×	276 0.8×	49	3.1k
Barbara Bigerna Italy	23	664 0.7×	929 1.6×	876 1.9×	172 0.5×	692 2.0×	35	2.5k

Countries citing papers authored by Ryan D. Cassaday

Since Specialization

Citations

This map shows the geographic impact of Ryan D. Cassaday's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan D. Cassaday with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan D. Cassaday more than expected).

Fields of papers citing papers by Ryan D. Cassaday

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan D. Cassaday. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan D. Cassaday. The network helps show where Ryan D. Cassaday may publish in the future.

Co-authorship network of co-authors of Ryan D. Cassaday

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan D. Cassaday. A scholar is included among the top collaborators of Ryan D. Cassaday based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan D. Cassaday. Ryan D. Cassaday is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Özcan, Muhıt, Ryan D. Cassaday, Ewa Zarzycka, et al.. (2025). Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study. Haematologica. 110(8). 1736–1746. 1 indexed citations

Lynch, Ryan C., Ryan D. Cassaday, Stephen D. Smith, et al.. (2024). Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up. Blood. 144(Supplement 1). 3043–3043. 1 indexed citations

Huang, Jennifer J., Emily C. Liang, Andrew J. Portuguese, et al.. (2024). Early prediction of severe ICANS after standard-of-care CD19 CAR T-cell therapy using gradient-boosted classification trees.. Journal of Clinical Oncology. 42(16_suppl). 7034–7034. 2 indexed citations

Appelbaum, Jacob, Kathryn Russell, Xueyan Chen, et al.. (2024). Hematopoietic stem cell transplant for adults with mixed phenotypic acute leukemia.. Journal of Clinical Oncology. 42(16_suppl). 6517–6517.

Oluwole, Olalekan O., Armin Ghobadi, Ryan D. Cassaday, et al.. (2024). Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.. Journal of Clinical Oncology. 42(16_suppl). 6531–6531. 3 indexed citations

Cassaday, Ryan D., et al.. (2024). Retrospective review of the toxicities and change in dosing patterns for pegaspargase in patients with acute lymphoblastic leukemia/lymphoma and T-cell lymphoma. Journal of Oncology Pharmacy Practice. 31(4). 534–544.

Huang, Jennifer J., Ryan Basom, Andrea Kalus, et al.. (2024). Autoimmune Outcomes in Patients with Concurrent Autoimmune Disease Receiving CD19 CAR T-Cell Therapy for Lymphoma. Blood. 144(Supplement 1). 7132–7132. 1 indexed citations

Kampouri, Eleftheria, Ryan Basom, Chris Davis, et al.. (2023). 2711. Viral encephalitis after chimeric antigen receptor (CAR)-modified T-cell therapy: A Retrospective Cohort Study. Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations

Cassaday, Ryan D., Olga Sala‐Torra, Philip A. Stevenson, et al.. (2023). Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia. Leukemia & lymphoma. 64(5). 927–937. 4 indexed citations

10.

Kantarjian, Hagop M., Wendy Stock, Ryan D. Cassaday, et al.. (2021). Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clinical Cancer Research. 27(10). 2742–2754. 29 indexed citations

11.

Stock, Wendy, Jae H. Park, Ashkan Emadi, et al.. (2021). Safety and Pharmacokinetics of Calaspargase Pegol in Adults with Newly Diagnosed Philadelphia-Negative ALL: A Phase 2/3 Study. Blood. 138(Supplement 1). 4406–4406. 1 indexed citations

12.

Cassaday, Ryan D., Jonathan R. Fromm, Mary‐Elizabeth M. Percival, et al.. (2020). Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia. Blood Advances. 4(14). 3239–3245. 19 indexed citations

13.

Graf, Solomon A., Ryan D. Cassaday, Karolyn Morris, et al.. (2020). Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 21(3). 176–181. 10 indexed citations

14.

Matesan, Manuela C., Darrell R. Fisher, Roger Wong, et al.. (2020). Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies. Journal of Nuclear Medicine. 61(9). 1300–1306. 2 indexed citations

15.

Cassaday, Ryan D., Oliver W. Press, John M. Pagel, et al.. (2019). Phase I Study of a CD45-Targeted Antibody–Radionuclide Conjugate for High-Risk Lymphoma. Clinical Cancer Research. 25(23). 6932–6938. 16 indexed citations

16.

Puronen, Camille E., Ryan D. Cassaday, Philip A. Stevenson, et al.. (2018). Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation–Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biology of Blood and Marrow Transplantation. 24(11). 2211–2215. 8 indexed citations

17.

Cassaday, Ryan D., Jonathan R. Fromm, Andrew J. Cowan, et al.. (2017). Radiographic and High-Throughput Sequencing (HTS)-Based Response Assessment after Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Updated Results of a Phase I/II Trial. Blood. 130. 2806–2806. 9 indexed citations

18.

Tseng, Yolanda D., Philip A. Stevenson, Ryan D. Cassaday, et al.. (2017). Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma. Biology of Blood and Marrow Transplantation. 24(2). 282–287. 9 indexed citations

19.

Onishi, Maika, Leona Holmberg, Andrei R. Shustov, et al.. (2013). Brentuximab Vedotin Administered To Platinum-Refractory Transplant Naïve Hodgkin Lymphoma Patients Can Increase The Proportion Achieving FDG-PET Negative Status. Blood. 122(21). 2106–2106. 2 indexed citations

20.

Cassaday, Ryan D. & Ajay K. Gopal. (2012). Allogeneic hematopoietic cell transplantation in mantle cell lymphoma. Best Practice & Research Clinical Haematology. 25(2). 165–174. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact